Trade
GlaxoSmithKline Pharmaceuticals share price
Balanced risk
You have to be logged in to add this to Watchlist.- ₹2,435.50(-0.31%)July 10, 2026 15:55:28 PM IST
- NSE
- BSE
- Vol : 24.59 K (NSE + BSE)Last 20 day avg : 191.12 K
GlaxoSmithKline Pharmaceuticals is trading -0.31% lower at Rs 2,435.50 as compared to its last closing price. GlaxoSmithKline Pharmaceuticals has been trading in the price range of 2,454.00 & 2,422.55. GlaxoSmithKline Pharmaceuticals has given -1.34% in this year & 1.02% in the last 5 days. GlaxoSmithKline Pharmaceuticals has TTM P/E ratio 37.33 as compared to the sector P/E of 26.80.There are 4 analysts who have initiated coverage on GlaxoSmithKline Pharmaceuticals. There are 1 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 277.86 Crores in its last quarter.Listed peers of GlaxoSmithKline Pharmaceuticals include Dr Reddy's Laboratories (-1.91%), Sun Pharmaceutical Industries (-0.19%), Divi's Laboratories (0.31%).The Mutual Fund holding in GlaxoSmithKline Pharmaceuticals was at 4.73% in 31 Mar 2026. The MF holding has decreased from the last quarter. The FII holding in GlaxoSmithKline Pharmaceuticals was at 4.62% in 31 Mar 2026. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Key Metrics
Updated on Jul 10, 2026, 06:02 PM UTC
- BetaLow volatility0.42Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityLower than industry0.01The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldHigher than industry2.34Annual dividends as a percentage of the stock price.
- PEG RatioIndicates overvaluation2.05The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
Price range
Day Range
|
| ||||
52 week range
|
| ||||
GlaxoSmithKline Pharmaceuticals News
GlaxoSmithKline Pharmaceuticals Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Dr Reddy's Laboratories | 1,245.50 | -1.91 | 1,03,954.01 | 18.63 | 3.14 | 0.63 | 2.34 |
| Sun Pharmaceutical Industries | 1,935.25 | -0.19 | 4,64,320.36 | 36.24 | 5.77 | 0.92 | 0.50 |
| Divi's Laboratories | 6,832.30 | 0.31 | 1,81,268.32 | 78.61 | 11.52 | 0.46 | 0.01 |
| Torrent Pharmaceuticals | 4,895.20 | -0.03 | 1,65,669.16 | 67.32 | 17.1 | 0.83 | 17.62 |
| Cipla | 1,438.75 | -0.20 | 1,16,228.75 | 22.95 | 3.87 | 0.87 | 0.81 |
Mutual Fund Ownership
View allGlaxoSmithKline Pharmaceuticals Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-05-13 | Audited Results & Dividend |
| 2026-02-09 | Quarterly Results |
| 2025-11-06 | Quarterly Results |
| 2025-08-01 | Quarterly Results |
| 2025-05-13 | Audited Results & Final Dividend |
About the company GlaxoSmithKline Pharmaceuticals
- IndustryBiotechnology & Drugs
- ISININE159A01016
- BSE Code500660
- NSE CodeGLAXO
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.
GlaxoSmithKline Pharmaceuticals Share Price FAQs
GlaxoSmithKline Pharmaceuticals is trading at 2435.50 as on Fri Jul 10 2026 10:25:28. This is -0.31% lower as compared to its previous closing price of 2443.10.
The market capitalization of GlaxoSmithKline Pharmaceuticals is 41440.34 Cr as on Fri Jul 10 2026 10:25:28.
The average broker rating on GlaxoSmithKline Pharmaceuticals is Buy. The breakup of analyst rating is given below -
- 1 analysts have given a strong buy rating
- 2 analysts have given a buy rating
- 1 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for GlaxoSmithKline Pharmaceuticals is 3356.00 whereas the 52 wk low is 2088.00
GlaxoSmithKline Pharmaceuticals can be analyzed on the following key metrics -
- TTM P/E: 37.33
- Sector P/E: 26.80
- Dividend Yield: 2.34%
- D/E ratio: 0.01
GlaxoSmithKline Pharmaceuticals reported a net profit of 1035.98 Cr in 2026.
The Mutual Fund Shareholding was 4.73% at the end of 31 Mar 2026.
Quick Links
EQUITY QUICK LINKS
GlaxoSmithKline Pharmaceuticals QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.